Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Equity for 12 consecutive years, with 0.4% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 45.0% to 0.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.4% through Dec 2025, up 45.0% year-over-year, with the annual reading at 0.45% for FY2025, 50.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.4% at Theravance Biopharma, up from 0.33% in the prior quarter.
  • The five-year high for Return on Equity was 15.09% in Q3 2022, with the low at 0.26% in Q3 2024.
  • Average Return on Equity over 5 years is 1.12%, with a median of 0.03% recorded in 2021.
  • The sharpest move saw Return on Equity skyrocketed 1498bps in 2022, then crashed -1526bps in 2023.
  • Over 5 years, Return on Equity stood at 0.2% in 2021, then soared by 1155bps to 2.09% in 2022, then plummeted by -111bps to 0.24% in 2023, then soared by 77bps to 0.05% in 2024, then surged by 838bps to 0.4% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.4%, 0.33%, and 0.31% for Q4 2025, Q3 2025, and Q2 2025 respectively.